New drug set to calm Parkinson’s tremors

LONDON: Scientists are launching the first human trials of a “life-changing” drug that can alleviate the outward signs of Parkinson’s disease.

The drug, NLX-112, tackles the shaking and twitchiness brought on by Parkinson’s treatments and could be available within a year.

The worst involuntary movements are caused by dyskinesia, a condition produced by the standard therapy for Parkinson’s, not by the disease itself.

Parkinson’s, a degenerative neurological condition with no cure, can cause a tremor, muscle stiffness and slowness of movement. The treatment can then drive twitches to disabling levels.

About 10 million people globally live with Parkinson’s.

As part of a year-long study, scientists from the American biotech company Neurolixis tested monkeys with Parkinson-like symptoms that had developed dyskinesia in response to levodopa.

The results, published in the Neuropharmacology journal, showed that NLX-112 reduced involuntary movements without diminishing the therapeutic effect of the levodopa. The new drug has also been tested on diabetes patients to treat pain and was found to be well tolerated and safe.

Human trials are being organised by a team at the Karolinska Institute in Sweden.

They follow a deal between the Michael J. Fox Foundation for Parkinson’s Research in New York and Parkinson’s UK to fund the ›1.5m clinical trials.

A public announcement is expected this week.

Michael J. Fox, a Hollywood actor, was diagnosed with Parkinson’s in 1991 at the age of 29. He said in an interview on Saturday: “Every step now is a frigging math problem, so I take it slow” and his career is on “pause”.

Dyskinesia makes everyday tasks, such as tying shoelaces or making a cup of tea, difficult or impossible. The main medication to treat it is amantadine, which can itself have challenging side effects.

NLX-112 works by targeting serotonin-producing brain cells. They are believed to contribute to dyskinesia by converting levodopa into dopamine and releasing it in an erratic manner. NLX-112 stabilises the flow.

Michael Gibson, 40, a television director from Lancashire, was diagnosed with Parkinson’s when he was 18. “Dyskinesia is absolutely the worst part of having Parkinson’s for me,” said Gibson, a father of two.

“I’m naturally a very sociable, outgoing person, but it’s a huge knock to my self-confidence when I’m out with my kids and people stare or make awful remarks. I’ve been told ‘You’re a disgrace’ because the sudden movements make people think I’m drunk.”

He added: “This new drug has the potential to be life-changing for me and lots of people with Parkinson’s. I can’t tell you how hard it is to live with the disease. And dyskinesia, which is a side effect of the medication, is worse than the Parkinson’s for me.”